RxDoctor Payments Data

Michael Daniel, MD

Interventional Cardiology · Humble, TXNPI 1275896649

Payments from drug & device makers

$13,272in general payments, 2019–2025

Across 298 payments — averaging $44.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$4K
  • Abbott$2K
  • Medtronic$1K
  • Shockwave Medical, Inc$1K
  • Philips North America LLC$741
  • Edwards Lifesciences$642
  • plus $4K from 39 others

What the payments were for

  • Travel & lodging$1,41311%
  • Food & beverage$11,85989%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,272 in reported general payments places this provider in the 55th percentile of 686 interventional cardiology providers in Texas.

See all interventional cardiology providers in Texas

Medicare billing

Part B allowed, 2024
$223,830
Medicare patients
1,191
Services billed
3,198

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban135$116,555
CamzyosMavacamten13$107,352
EntrestoSacubitril/Valsartan65$77,787
XareltoRivaroxaban59$60,086
Repatha SureclickEvolocumab51$53,168
JardianceEmpagliflozin15$25,911
FarxigaDapagliflozin Propanediol13$10,944
BrilintaTicagrelor14$10,660
Rosuvastatin Calcium190$2,799
ClopidogrelClopidogrel Bisulfate183$1,896
Metoprolol Succinate117$1,884
Bumetanide31$1,774
Nifedipine ErNifedipine67$1,663
Atorvastatin Calcium137$1,263
Carvedilol123$1,232

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$165$116,555135 claims
E.r. Squibb & Sons, L.L.C.Camzyos$318$107,35213 claims
NovartisEntresto$231$77,78765 claims
Johnson & JohnsonXarelto$123$60,08659 claims
Boehringer IngelheimJardiance$46$25,91115 claims
AstraZenecaFarxiga, Brilinta$61$21,60327 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 686 interventional cardiology providers in Texas.

Other interventional cardiology in Humble

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →